Unknown

Dataset Information

0

Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta.


ABSTRACT: The induction of regulatory T (T reg) cells holds considerable potential as a treatment for autoimmune diseases. We have previously shown that CD4+CD25hi T reg cells isolated from patients with active rheumatoid arthritis (RA) have a defect in their ability to suppress proinflammatory cytokine production by CD4+CD25- [corrected] T cells. This defect, however, was overcome after anti-tumor necrosis factor (TNF)-alpha antibody (infliximab) therapy. Here, we demonstrate that infliximab therapy gives rise to a CD4+CD25hiFoxP3+ T reg cell population, which mediates suppression via transforming growth factor (TGF)-beta and interleukin 10, and lacks CD62L expression, thereby distinguishing this T reg cell subset from natural T reg cells present in healthy individuals and patients with active RA. In vitro, infliximab induced the differentiation of CD62L- T reg cells from CD4+CD25- T cells isolated from active RA patients, a process dependent on TGF-beta. In spite of the potent suppressor capacity displayed by this CD62L- T reg cell population, the natural CD62L+ T reg cells remained defective in infliximab-treated patients. These results suggest that anti-TNF-alpha therapy in RA patients generates a newly differentiated population of T reg cells, which compensates for the defective natural T reg cells. Therefore, manipulation of a proinflammatory environment could represent a therapeutic strategy for the induction of T reg cells and the restoration of tolerance.

SUBMITTER: Nadkarni S 

PROVIDER: S-EPMC2118431 | biostudies-literature | 2007 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta.

Nadkarni Suchita S   Mauri Claudia C   Ehrenstein Michael R MR  

The Journal of experimental medicine 20070102 1


The induction of regulatory T (T reg) cells holds considerable potential as a treatment for autoimmune diseases. We have previously shown that CD4+CD25hi T reg cells isolated from patients with active rheumatoid arthritis (RA) have a defect in their ability to suppress proinflammatory cytokine production by CD4+CD25- [corrected] T cells. This defect, however, was overcome after anti-tumor necrosis factor (TNF)-alpha antibody (infliximab) therapy. Here, we demonstrate that infliximab therapy give  ...[more]

Similar Datasets

| S-EPMC10660495 | biostudies-literature
2010-06-24 | E-GEOD-19821 | biostudies-arrayexpress
2010-01-28 | GSE19821 | GEO
| S-EPMC4925013 | biostudies-literature
| S-EPMC5509678 | biostudies-literature
| S-EPMC2483439 | biostudies-literature
| S-EPMC7385392 | biostudies-literature
2012-01-01 | E-GEOD-33377 | biostudies-arrayexpress
2022-06-06 | GSE198520 | GEO
2012-01-01 | GSE33377 | GEO